BRWM
ATYR

Blue Rock Wealth Management’s aTyr Pharma ATYR Stock Holding History

Blue Rock Wealth Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,000
Closed -$12.3K – 113
2025
Q3 		$12.3K Sell
17,000
-3,000
-15% -$13.6K 0.01% 107
2025
Q2 		$101K Buy
+20,000
New +$78.7K 0.07% 99

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blue Rock Wealth Management's ATYR Position: Q4 2025 in Review

Blue Rock Wealth Management sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 17,000 shares — an estimated $12.3K sold.

Blue Rock Wealth Management first reported a position in ATYR in Q2 2025 and held it in 2 quarters. The position peaked at $101K in Q2 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • Blue Rock Wealth Management reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • Blue Rock Wealth Management sold 17,000 aTyr Pharma shares in Q4 2025, an estimated $12.3K.
  • Blue Rock Wealth Management first reported a position in aTyr Pharma in Q2 2025 and held it in 2 quarters.
  • Blue Rock Wealth Management's aTyr Pharma position peaked at $101K in Q2 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Blue Rock Wealth Management's 13F filing for Q4 2025, filed 20 Jan 2026.